524 results about "Cell model" patented technology

The present invention relates to a computer-implemented method and system for optimizing geometric configurations within thermal energy transfer device comprising at least one thermal energy exchange channel to enhance performance. The method involves obtaining target design criteria for a physical object and defining a unit cell dimensioned such that the thermal energy transfer channel is formed by a matrix of N1 x N2 identical unit cells. Shape optimization is performed at the unit cell level by iteratively modifying the boundary surfaces of solid structures within a unit cell based on criteria including performance. Optimized design parameters are outputted and transferred to production equipment for creating an optimized thermal energy transfer device. This device comprises a matrix of structures arrayed in at least one dimension, derived from optimized unit cell models.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine prescription efficacy quantification method and system.The method comprises the steps that chemical component spectrums, pharmacodynamic substance contents and biological activity indexes of traditional Chinese medicines forming a prescription are obtained; constructing a multi-target regulation and control network by combining a traditional Chinese medicine-target interaction database according to the chemical component spectrum, the pharmacodynamic substance content and the biological activity index, identifying a core efficacy pathway cluster by adopting a Louvain algorithm, and calculating a pathway activation intensity value by adopting a pathway target membership weighting model; according to the core efficacy pathway cluster, establishing a mapping relation between the core efficacy pathway cluster and traditional Chinese medicine efficacy terms through ontology and semantic mapping, and according to pathway activation intensity values, generating a prescription efficacy intensity vector through a weighted aggregation model; according to the efficacy intensity vector of the prescription, verifying and correcting the network weight through an in-vitro cell model, and generating the efficacy quantification of the prescription in combination with the clinical syndrome calibration coefficient. Therefore, the problems of single data dimension and insufficient quantification result accuracy in the prior art are solved.

The invention relates to the technical field of medicines, in particular to a construction method and application of a photothermal conversion platform for treating osteoarthritis by regulating synovial macrophage polarization. According to the present invention, the M2 membrane-structured black phosphorus selenium carbon body (M2-BPSeC) photo-thermal nano-platform is innovatively provided, the triple functions of bionic targeting delivery, precise thermal control intervention and immune microenvironment remodeling are integrated, and the excellent synergistic treatment effect is represented in the in-vitro cell model and the OA animal model. The technology breaks through the technical bottleneck that traditional treatment is insufficient in targeting and single in intervention dimension, precise functional coupling of the physical thermal effect and immunoregulation is achieved for the first time, and a brand new strategy of targeting-temperature control-immunity integration is provided for osteoarthritis treatment. The efficient and controllable preparation process and the remarkable multi-dimensional treatment effect open up a new path for cartilage regeneration and immune balance regulation and control.

The invention provides kelp fucoidin with low molecular weight and high anti-anaphylaxis as well as a preparation method and application thereof, and belongs to the technical field of food processing. The preparation method comprises the following steps: mixing kelp fucoidin with water to obtain a kelp fucoidin solution; and mixing the kelp fucoidin solution with H2O2 and Vc, reacting, adjusting the pH value, dialyzing and freeze-drying to obtain the kelp fucoidin with low molecular weight and high anti-allergic property. The H2O2-Vc degradation system is innovatively applied to preparation of the low-molecular-weight kelp fucoidin and improvement of the anti-allergic activity of the low-molecular-weight kelp fucoidin. In the degradation process, the chemical composition of the fucoidin is partially changed, but monosaccharide types and functional groups are not influenced. Through multiple ways of cell model and animal model experiments, the degraded laminaria fucoidin is more prominent in anti-allergic activity. Technical support is provided for development of seaweed-derived anti-allergic functional active substances, and high-valued utilization of kelp resources in the fields of functional food and medicines is further promoted.

The invention discloses a three-dimensional woven composite material reverse design method based on a generative adversarial neural network. The method comprises the following steps: selecting three-dimensional woven composite material samples of different process structures through super-Latin sampling; a Python script is combined with TexGen textile modeling software to generate a three-dimensional woven composite material unit cell model, and Abaqus is imported to calculate the mechanical property of the material; normalized coding is carried out on the process structure of the three-dimensional woven composite material, mechanical properties of the material are combined to serve as a data set, a generative adversarial neural network is trained, and hyper-parameters are optimized through Bayesian. According to the method, mapping between the technological parameters and the mechanical properties of the three-dimensional woven composite material is established through the generative adversarial neural network model, the design, research and development efficiency of the three-dimensional woven composite material can be improved by more than 50%, and the structural design accuracy and the performance prediction accuracy of the three-dimensional woven composite material are improved.

The invention discloses a piezoelectric ceramic fatigue life analysis method based on macro and micro multi-scale. The method comprises the following steps: firstly, automatically establishing a microcosmic unit cell model based on a Python script, realizing automatic assignment of material parameters and application of periodic boundary conditions, and calculating microcosmic unit cell homogenization mechanical parameters; then constructing a macroscopic driver model, inputting microscopic parameters as material attributes, and performing macroscopic fatigue life prediction and damage distribution simulation in combination with a Miner linear damage accumulation theory; and finally, through macro-micro coupling analysis, transmitting the strain of the macroscopic maximum stress unit to the micro model, and researching the intergranular stress distribution characteristics and the interface damage evolution law of the piezoelectric ceramic. According to the method, a multi-scale modeling strategy is adopted, cross-scale fatigue performance prediction from the micro grain scale to the macro structure scale is achieved, and an effective means is provided for reliability design and service life evaluation of the piezoelectric ceramic driver.

The invention belongs to the technical field of microorganisms, and particularly relates to an oligopeptide from lactobacillus plantarum extracellular vesicles and application of the oligopeptide. Specifically, the lactobacillus plantarum extracellular vesicles can recover the skin barrier; the expression of proinflammatory factors in a cell inflammation model can be reduced, and a relatively good anti-inflammatory effect is achieved. Metabolome analysis shows that effective substances having effects on skin barrier injury comprise oligopeptide KLQ; kLQ can regulate skin barrier related gene expression in the SDS-induced damaged cell model; and the expression of skin inflammation-related genes in the SDS-induced damaged cell model is regulated, so that the SDS-induced SDS-induced damaged cell model can be used as a medicine for treating skin barrier injury.

The invention provides a TF and Her2 targeting bispecific antibody coupling drug as well as a preparation method and application thereof, and belongs to the technical field of biological drug preparation. The bispecific antibody provided by the invention can target TF and / or Her2 antigens in tumor cells, and has the advantages of high stability, easiness in expression, purification and coupling and the like. The bispecific antibody can be specifically combined with a tumor surface antigen and internalized into tumor cells, so that the tumor cells can be specifically killed. The bispecific antibody coupling drug prepared on the basis of the bispecific antibody has a good tumor inhibition effect in a cell model and an animal model, is nontoxic and harmless to animals, and has an excellent cancer treatment potential.

The invention discloses a group of pyemia specific biomarkers and application thereof, and belongs to the field of medical detection.The biomarkers are formed by combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H, according to the invention, seven core proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened from TMT proteomics of serum of a clinical hemorrhagic patient, and four more important proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are obtained by further screening the seven proteins in a hemorrhagic cell model and the clinical hemorrhagic patient. The four proteins are verified again in serum of a hemorrhagic mouse animal experiment and an expanded-scale clinical hemorrhagic patient, and the potential of the four core proteins as serum biomarkers for early diagnosis of hemorrhagic disease is determined.

The invention discloses a method and a system for measuring an electrode constant of an oil conductivity valuing device, relates to the technical field of measurement, and breaks through the limitation of roughly taking an average value of an area of a polar plate traditionally by constructing an actual conductance cell model and defining parameter information, accurately deduces a conductance cell constant, and reversely calculates an effective relative area to determine the electrode constant. According to the method, the coaxial annular structure characteristics are attached, the influence of the edge effect and electric field line diffusion is avoided, and electrode constant calculation is more scientific and rigorous. Therefore, the accuracy of the constant value of the oil conductivity standard substance is guaranteed, a reliable reference is provided for verification and calibration of an oil conductivity meter, an effective oil conductivity measurement result is ensured, the electrostatic accident risk is reduced from the source, and the oil fuel quality and safety management and control are enhanced. The problems that an existing coaxial annular cylinder type electrode conductance cell is not strict in constant calculation and low in standard value credibility are effectively solved, and the electrode constant measurement accuracy of the oil conductivity valuing device is remarkably improved.

The invention belongs to the field of biological medicine, and particularly relates to application of deaminotyrosine in preparation of a medicine for treating vascular calcification symptoms. The invention finds that deaminotyrosine can significantly reduce the vascular calcification degree of an in-vitro cell model and an in-vivo animal model by inhibiting osteogenic differentiation and calcium salt deposition of vascular smooth muscle cells; therefore, the invention provides a new application of the deaminated tyrosine or pharmaceutically acceptable salt, ester, solvate or prodrug thereof in preparation of drugs for treating vascular calcification symptoms. The invention also provides a pharmaceutical composition, which takes deaminated tyrosine as an active component, and provides a brand new drug choice for clinical prevention and treatment of vascular calcification.

The invention discloses a combined evaluation method for in-vitro and in-vivo red fading and relieving effects of cosmetic raw materials, which comprises the following steps: in-vitro model evaluation: inducing a human immortalized umbilical vein endothelial cell model by adopting TNF-alpha, and detecting the secretion amount of a prostacyclin I2 factor to obtain a score of an in-vitro model; in-vivo model evaluation: adopting a chick embryo chorioallantoic membrane model, and obtaining a score of the in-vivo model according to the degree of vasoconstriction caused by the to-be-detected raw material sample acting on the chick embryo chorioallantoic membrane; and comprehensive evaluation: based on the score of the in-vitro model and the score of the in-vivo model, comprehensively evaluating the red fading and relieving efficacy of the raw material sample to be tested. According to the technical scheme, the defect that in the prior art, no cosmetic raw material soothing efficacy evaluation method for the vascular reactivity increasing mechanism exists is overcome, efficacy evaluation is more accurate, the method has the advantages of being comprehensive, short in test period, easy to operate, economical and convenient, and an effective reference basis is provided for screening and compounding schemes of red fading and soothing raw materials.

The invention provides a method for inducing HL-60 cells to be differentiated into neutrophil-like cells, and belongs to the technical field of cell culture. According to the method, the induced differentiation efficiency of the HL-60 cells to the neutrophil-like cells (D-HL-60) and the cell quality are remarkably improved, high-proportion functional D-HL-60 cells can be obtained, a good motility rate can be maintained, and a stable and reliable cell model is provided for researching a neutrophil differentiation mechanism, screening related drugs and analyzing immune functions. Particularly, the functional D-HL-60 cells obtained on the basis of the method can be used as an ideal model, deep analysis of neutrophil trapping nets (NETs) in inflammation and tumor pathological mechanisms is assisted, and an experimental basis is provided for development of therapeutic strategies of targeted NETs.

The invention discloses a method for researching the corrosion resistance behavior of zinc alloy based on a first principle. The method comprises the following steps: firstly, retrieving a zinc primitive cell model from a material database and carrying out structure optimization; performing crystal face cutting, cell expansion and re-structure optimization to obtain a zinc plate model; then aluminum atom random replacement doping processing is carried out, and optimization is carried out to obtain a doping model; performing static self-consistent calculation to obtain surface energy, and screening out the most stable doping model; fixing two layers of atoms at the bottom of the most stable doping model, performing chloride ion adsorption calculation and structure optimization, and calculating adsorption energy to determine a most stable adsorption site; and finally, carrying out electronic structure calculation of state density and a work function, and representing the corrosion resistance of the zinc alloy. According to the method, a zinc alloy corrosion micromechanism is deeply analyzed, theoretical guidance is provided for component optimization and corrosion resistance improvement, and compared with a traditional experimental method, the research and development cost and time are remarkably reduced, the research efficiency is improved, and the method has important theoretical and practical application value.

The invention provides an SNP (Single Nucleotide Polymorphism) marker for targeted identification of systemic lupus erythematosus of children and application of the SNP marker. A new SNP site (RS25671007) is identified in a child systemic lupus erythematosus patient through whole exon sequencing, the site is located at the 734th pair of basic groups of a PABPC3 gene, and mutation from C to T exists at the site, or mutation from threonine to isoleucine exists in coded amino acid. In addition, in-vitro cell model experiments prove that the SNP causes significant up-regulation of the antibody type transformation function, and the SNP can be used as a reference marker for risk stratification or medication guidance of early targeted diagnosis, detection, gene evaluation and the like of systemic lupus erythematosus of children.

The invention relates to the technical field of nuclear reactor fuel element analysis, in particular to an irradiated zirconium alloy plasticity limit prediction method based on a crystal plasticity finite element, which comprises the following steps: establishing a three-dimensional polycrystalline representative body cell model conforming to the actual grain size of zirconium alloy; based on a crystal plasticity theoretical model, zirconium alloy material parameters are obtained through calculation; boundary conditions and load conditions are determined, finite element calculation is executed in combination with material parameters, and an element stiffness matrix of each increment step is output; assembling the unit stiffness matrix, and obtaining a macroscopic stress-strain matrix of the three-dimensional polycrystal cell model through a homogenization method; and substituting the macroscopic stress-strain matrix into the Rice theoretical criterion, traversing the macroscopic stress-strain matrix of each increment step, and determining the plastic strain meeting the judgment critical condition. According to the method, accurate finite element plastic limit analysis can be carried out on the irradiation material, and the plastic limit strain of the zirconium alloy under the irradiation condition can be accurately judged.

The invention discloses a fuel cell hybrid power system energy management strategy considering system heat dissipation performance. The strategy comprises the following steps: establishing a fuel cell system model, a cell model, a fuel cell voltage attenuation model and a power cell capacity attenuation model; carrying out hybrid power system power distribution based on a dynamic planning method; aiming at a dynamic planning power distribution result, respectively adopting a threshold power method and an average power method to correct the output power of the fuel cell, so that the heat generated by the electric pile is matched with the heat dissipation of a radiator, and the temperature of the electric pile is maintained in a reasonable range; and finding a power distribution result which enables the whole life cycle cost to be lowest and meets the heat dissipation requirement. According to the invention, the method is suitable for various fuel cell systems such as mobile and fixed fuel cell systems, the operability is strong, the system performance is effectively improved, the heat dissipation performance of the system is considered, and the life cycle cost of the hybrid power system is reduced.

The invention provides an in-vitro anti-saccharification effect evaluation method and application thereof, and belongs to the technical field of skin saccharification resistance. A photoaging fibroblast model is adopted, after induction of an inducer, anti-saccharification evaluation is carried out by detecting the contents of collagen and waveform protein after application of a substance to be detected, and it is proved that the anti-saccharification effect of the anti-saccharification substance in the cell model is consistent with the result in human body effect evaluation; the evaluation method can be applied to screening and evaluation of anti-skin saccharification substances.

The invention discloses a wing structure multi-level modeling method, device, equipment and medium, and relates to the field of structure modeling simulation and wing structure analysis, and the method comprises the steps: decomposing a target wing into a 0-level simplified beam model, a 1-level unit cell model and a 2-level sub-model; performing order reduction analysis on the 1-level unit cell model, constructing an equivalent section attribute matrix, and establishing a wing simplified model matched with the beam element finite element stiffness matrix; building a sub-model simulation database based on multi-working-condition simulation, applying a generalized load and a typical external load, and obtaining displacement field data under each working condition; according to the displacement field data, extracting a displacement field boundary condition and a POD coefficient of the stress field data, and constructing a data driving sub-model; and performing multi-level model analysis on the target wing according to the wing simplified model and the data driving sub-model. The mechanical property and response of the wing structure under different working conditions can be efficiently and accurately simulated and analyzed.

The invention belongs to the technical field of fermentation and metagen preparations, and particularly relates to application of bifidobacterium breve metagen in the aspects of scavenging free radicals and relieving oxidative aging. According to the present invention, the oxidative free radical scavenging experiment results show that the bifidobacterium breve NKU BB 1-2 metagen has good oxidative free radical scavenging ability, and has good scavenging ability on hydroxyl free radicals, superoxide anions and DPPH free radicals; meanwhile, through component analysis, it is found that the bifidobacterium breve NKU BB 1-2 metagen contains various antioxidant and anti-aging bioactive substances such as flavonoids, indoles, amino acids, bile acids and ceramides; a cell model experiment verifies that the bifidobacterium breve NKU BB 1-2 metagen can obviously relieve oxidative damage to the cells and improve the oxidation resistance of the cells, so that oxidative aging is relieved.

The invention discloses application of piperlongumine in preparation of a medicine for treating virus-induced myocardial fibrosis. According to the application, an in-vivo myocardial fibrosis model is constructed by infecting a BALB / c mouse with a CVB3 virus, and meanwhile, an in-vitro cell model for proliferation and differentiation of primary myocardial fibroblasts is constructed by inducing TGF-beta1. Results prove that when the piperlongumine is applied to the acute stage (1-14 days), the chronic stage (14-28 days) and the whole course (1-28 days) of the viral myocarditis, the myocardial fibrosis of the viral myocarditis can be remarkably improved, the cardiac function is improved, and the curative effect of the piperlongumine applied to the whole course is superior to that of the piperlongumine applied to the acute stage and the chronic stage; the specific mechanism is that Smad2 / 3 and p-38 / YAP pathways jointly play a role in inhibiting myocardial fibrosis.

The invention discloses a construction and verification method of an HEK293T cell line capable of stably overexpressing human ANT2, which comprises the following steps: cloning a human ANT2 gene, constructing the human ANT2 gene into a lentivirus expression plasmid pLVX-TRE3G, co-transfecting the lentivirus expression plasmid pLVX-TRE3G and a helper plasmid pLVX-Tet3G into an HEK293T-ACE2 cell, and carrying out puromycin and G418 pressurized screening and Western blot identification to obtain the HEK293T cell line capable of stably overexpressing human ANT2. A result shows that the expression quantity of the ANT2 is the highest when the HEK293T-ACE2-ANT2 cell is induced for 12 hours at the Doxycycline of 6mg / L; when the ANT2 is induced to express, the virus nucleic acid load and the N protein expression level after SARS-CoV-2 infection are obviously reduced, which indicates that the ANT2 has an inhibition effect on SARS-CoV-2 infection replication, and a cell model and an experimental basis are provided for exploring the effect of the ANT2 in virus infection resistance.

This application discloses an artificial intelligence-based method, apparatus, device, and medium for 3D cell structure reconstruction, relating to the field of cell reconstruction. The method includes determining cross-modal fusion features using a multi-scale feature encoder based on point cloud data in the same coordinate system and pre-defined biological prior features, including local feature extraction, global feature extraction based on multi-head relative self-attention, and cross-modal feature fusion; performing dimensionality reduction using an improved local linear embedding manifold learning algorithm based on the cross-modal fusion features; determining topology-enhanced high-dimensional features using a graph convolutional network based on spatial proximity, feature similarity, and biological relevance, using point cloud data in the same coordinate system, pre-defined biological prior features, cross-modal fusion features, and low-dimensional features preserving topological relationships; and performing 3D reconstruction using a decoder based on the topology-enhanced high-dimensional features. This application can improve the accuracy and mechanistic interpretability of 3D cell models.

The invention discloses application of dikafen phenolic acid and ester derivatives thereof in preparation of medicines for treating pulmonary fibrosis. On an MRC-5 cell model induced by TGF-beta1, the bikafen phenolic acid and the multiple ester derivatives thereof show the activity of inhibiting alpha-SMA and COL1A1 protein expression; on a bleomycin-induced pulmonary fibrosis mouse model, the dimethyl ester derivative of the dikafen phenolic acid shows a good protective effect on experimental animals. Therefore, the dicafen phenolic acid and the ester derivative thereof have good application in the field of preparation of medicines for treating pulmonary fibrosis diseases.

This invention discloses a hepatocyte model with silencing or overexpression of LCMT1 and its construction method, comprising: passage and seeding cells in logarithmic growth phase into well plates; diluting plasmid siRNA1 or siRNA2 or an overexpression plasmid to an appropriate concentration, and then mixing it with transfection reagent dilution to obtain a transfection mixture; washing the cells in each well of the plate and adding another culture medium, then gently dripping the transfection mixture into the well plate, shaking well, and culturing in a cell culture incubator for a period of time; replacing the culture medium with complete culture medium without antibiotics to obtain the constructed hepatocyte model with silencing or overexpression of LCMT1. This invention, by constructing a hepatocyte model with silencing or overexpression of LCMT1 in the liver, allows for validation experiments to be conducted to study the development mechanism of liver fibrosis. It is suitable for widespread application in various laboratories and provides an experimental model basis for research on liver fibrosis and drug trials.

The invention discloses application of beta-nicotinamide mononucleotide in regulation and control of gene editing efficiency, belongs to the field of gene editing treatment, and finds that the beta-nicotinamide mononucleotide (NMN) can efficiently inhibit the activity of CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13 systems in a broad-spectrum manner for the first time. The application comprises emergency blocking of off-target effect in gene editing clinical treatment, biological safety prevention and control of a virus vector gene editing system, and CRISPR activity regulation and control of in-vitro non-diagnostic purpose. Experiments show that NMN can inhibit CRISPR-mediated gene damage and cell death in a cell model, the inhibition efficiency in an in-vitro enzyme digestion system reaches 68.7%, and cell growth or transfection efficiency is not affected. The invention provides an innovative solution for safe application of CRISPR (clustered regularly interspaced short palindromic repeats) technology, and the NMN is approved to be taken orally as a health care product, so that the NMN has extremely strong clinical application potential. Compared with the existing CRISPR (clustered regularly interspaced short palindromic repeats)-resistant protein or synthetic small-molecule inhibitor, the NMN has the advantages of endogenous property, high biocompatibility, good oral safety and the like.

The invention belongs to the technical field of natural pharmaceutical chemistry, and particularly relates to a novel iridoid compound, namely, uncarcinin, separated from wingceltis, a pharmaceutically acceptable isomer of the novel iridoid compound, a wingceltis extract containing the novel iridoid compound, and a preparation method and application of the novel iridoid compound. The chemical structure of the utazonine is shown as a formula I, and the absolute configuration of the utazonine is (1S, 3S, 3aR, 4R, 7aS). The invention also provides a method for extracting the compound or the extract from the stem of the wingceltis, and purifying by combining pH gradient extraction with silica gel column chromatography, semi-preparative high performance liquid chromatography and gel chromatography to obtain the compound or the extract. The wingceltis cycline, the isomer of the wingceltis cycline, the wingceltis extract containing the wingceltis cycline or the pharmaceutical composition show remarkable gastric mucosa protection activity in an in-vitro cell model, particularly, the protection rate of the wingceltis cycline to ethanol-induced human gastric mucosa epithelial cell (GES-1) injury at the concentration of 50 mu M can reach 5.21%, and the wingceltis cycline, the isomer of the wingceltis cycline, the wingceltis extract containing the wingceltis cycline or the pharmaceutical composition show definite gastric mucosa protection activity.

The application provides a bispecific antibody conjugate drug targeting TF and Her2, and a preparation method and application thereof, and belongs to the technical field of biological drug preparation. The bispecific antibody provided by the application can target TF and / or Her2 antigens in tumor cells, has high stability, and has the advantages of easy expression, purification and conjugation. The bispecific antibody can specifically bind to tumor surface antigens and be internalized into tumor cells, and can specifically kill tumor cells. The bispecific antibody conjugate drug prepared based on the bispecific antibody has good tumor inhibition effect in a cell model and an animal model, is non-toxic and harmless to animals, and has excellent potential for treating cancer.

The application discloses a two-dimensional woven composite material geometry modeling method, device, equipment and medium, relates to the technical field of composite material structure design and modeling, and is used for solving the technical problems that the simulation model precision and reliability are low in the prior art. The method comprises the following steps: an initial matrix model is created by using a random distribution algorithm and a Boolean subtraction operation; a two-dimensional woven unit cell model is created according to a preset yarn space trajectory formula; a multi-layer two-dimensional woven fiber bundle model is created according to a plurality of two-dimensional woven unit cell models; a reserved fiber bundle matrix model is created by performing a difference set on the initial matrix model and the multi-layer two-dimensional woven fiber bundle model; and a two-dimensional woven three-dimensional model containing random pores is created by in-situ assembly of the reserved multi-layer fiber bundle matrix model and the multi-layer two-dimensional woven fiber bundle model. Therefore, the simulation model precision and reliability can be improved by using the technologies of "random distribution algorithm, Boolean subtraction operation, reserved position and in-situ assembly".

The invention discloses a human immortalized pure renal cyst cell line SRC-X1 and application thereof, and belongs to the field of microbial animal cell lines. The human immortalized pure renal cyst cell line is named as SRC-X1, the cell line is preserved in the China Center for Type Culture Collection on September 19, 2025, and the preservation number is CCTCC NO: C2025303. The human immortalized pure renal cyst cell line SRC-X1 is applied to preparation, screening or evaluation of renal cyst treatment drugs. The invention also discloses the application of the human immortalized pure renal cyst cell line SRC-X1 as a renal cyst cell model. The human immortalized pure renal cyst cell line SRC-X1 is applied to renal cyst basic or clinical research as an experimental material.